All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

Iomab-B Prior to Allogeneic HCT Improves Durable Complete Remission Rate in Older Patients With R/R AML

February 19th 2023

High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.

Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD

February 19th 2023

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.

Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL

February 19th 2023

Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.

Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC

February 19th 2023

The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.

Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple Myeloma

February 19th 2023

Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.

89Zr-DFO-girentuximab Showcases Sensitivity, Specificity for Clear Cell RCC Imaging

February 19th 2023

89Zr-DFO-girentuximab demonstrated sensitivity and specificity thresholds that were exceeded by 3 independent readers for PET/CT imaging of clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

Cabozantinib Plus Nivolumab/Ipilimumab Shows Notable PFS Improvement in Intermediate-Risk, Advanced RCC

February 18th 2023

The combination of frontline cabozantinib, nivolumab, and ipilimumab led to a greater improvement in progression-free survival in patients with intermediate- vs poor-risk advanced renal cell carcinoma.

Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple Myeloma

February 18th 2023

Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.

Cabozantinib After CPI-Based Combination Therapy Showcases Early Efficacy in Advanced RCC

February 18th 2023

Treatment with cabozantinib elicited responses in patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who had progressed after first-line treatment with checkpoint inhibitor–based combination therapy.

Orca-T Leads to High RFS Rates in Acute Leukemias and MDS

February 18th 2023

Treatment with the cellular therapy Orca-T produced an improved graft-vs-host-disease and relapse-free survival rate in patients with high-risk myelodysplastic syndrome or acute leukemias.

Atezolizumab/Chemotherapy Trends Toward Improved OS in Urothelial Carcinoma

February 18th 2023

First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

Nivolumab Displays Sustained Survival Benefits in Urothelial Carcinoma

February 18th 2023

At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.

Atezolizumab Monotherapy Falls Short in Exploratory OS Analysis in Untreated Locally Advanced or Metastatic Urothelial Cancer

February 18th 2023

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab Produces High DFS Rates in BCG-unresponsive NMIBC

February 18th 2023

Pembrolizumab monotherapy led notable antitumor activity with manageable toxicity in patients with Bacillus Calmette-Guérin–unresponsive, papillary high-risk non–muscle-invasive bladder cancer

Rucaparib Bests Physician's Choice for BRCA+ mCRPC

February 17th 2023

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC

February 17th 2023

The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

February 17th 2023

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUC

February 17th 2023

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

Potential Biomarkers of Response Identified for Enfortumab Vedotin in Advanced Urothelial Cancer

February 17th 2023

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.